标题
Radionuclide Therapy for Neuroendocrine Tumors
作者
关键词
Carcinoid tumors, PRRT, Radiolabeled somatostatin analogs, Lutetium, NETTER-1
出版物
Current Oncology Reports
Volume 19, Issue 2, Pages -
出版商
Springer Nature
发表日期
2017-02-20
DOI
10.1007/s11912-017-0567-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
- (2016) Murali Kesavan et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials
- (2016) Mauro Cives et al. CURRENT OPINION IN ONCOLOGY
- Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
- (2016) Dik J. Kwekkeboom et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer
- (2016) Lisa Bodei et al. SEMINARS IN NUCLEAR MEDICINE
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
- (2015) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores
- (2015) Evanthia Diakatou et al. CLINICAL ENDOCRINOLOGY
- Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
- (2015) Amir Sabet et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
- (2015) Stefano Severi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET
- (2015) Annarita Ianniello et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
- (2015) Seong-Jang Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term results of PRRT in advanced bronchopulmonary carcinoid
- (2015) Annapaola Mariniello et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms: New Diagnostic, Prognostic, and Therapeutic Markers
- (2015) Daniel Kaemmerer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
- (2015) E. I. van Vliet et al. JOURNAL OF NUCLEAR MEDICINE
- Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy
- (2015) Phillip G. Claringbold et al. NEUROENDOCRINOLOGY
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
- (2014) Giovanni Paganelli et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
- (2014) G. Kong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
- (2014) C. Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
- (2014) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2014) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
- (2014) C. Kratochwil et al. MOLECULAR IMAGING AND BIOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
- (2013) E. Seregni et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
- (2013) A. Romer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
- (2012) Linda Villard et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Downsizing by Internal Radiation
- (2011) Samer Ezziddin et al. CLINICAL NUCLEAR MEDICINE
- The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
- (2011) T.W. Barber et al. EJSO
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
- (2011) Jolanta Kunikowska et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
- (2011) Anna Sowa-Staszczak et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
- (2011) S. Khan et al. JOURNAL OF NUCLEAR MEDICINE
- Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
- (2010) Su-Jung Kim et al. BMC CANCER
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- (2010) David L. Bushnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
- (2010) M. van Essen et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
- (2010) Stefan E. Pool et al. SEMINARS IN NUCLEAR MEDICINE
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application
- (2009) Maralyn R. Druce et al. NEUROENDOCRINOLOGY
- Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
- (2009) Daniel Kaemmerer et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
- (2008) Bart de Keizer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
- (2008) Martijn van Essen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation